Table 1

Baseline characteristics (unweighted and weighted) of the DCCT subcohort (n = 518) versus the full DCCT cohort (n = 1,441), and the baseline summaries of the three biomarkers

UnweightedWeighted*Full cohort
Age (years)27 (22, 32)27 (21, 32)27 (22, 32)
Diabetes duration (months)55 (30, 115)50 (29, 107)51 (28, 109)
AER (mg/24 h)11.5 (7.2, 18.7)11.5 (7.2, 18.7)11.5 (7.2, 18.7)
eGFR (mL/min/1.73 m2)124.8 (117.9, 133.1)124.9 (117.9, 133.9)125 (118, 134)
BMI (kg/m2)23.4 (21.6, 25.3)23.3 (21.5, 25.3)23.3 (21.5, 25.2)
Triglycerides (mg/dL)70 (54, 93)69 (54, 91)70 (55, 94)
LDL (mg/dL)105 (88, 126)104 (87, 124)107 (91, 127)
HDL (mg/dL)48 (42, 57)50 (42, 57)49 (42, 57)
SBP (mmHg)114 (108, 122)114 (108, 122)114 (108, 122)
Diastolic blood pressure (mmHg)74 (68, 80)74 (68, 80)72 (68, 80)
Pulse (bpm)76 (68, 84)76 (68, 84)76 (68, 84)
HbA1c (%; mmol/mol)8.6 (7.6, 9.8); 70 (60, 84)8.5 (7.6, 9.8); 69 (60, 84)8.7 (7.8, 9.9); 72 (62, 85)
Treatment group (% intensive)46.348.749.3
Cohort (% primary)45.250.050.4
Sex (% male)52.352.952.8
Smoking (%)19.318.418.5
AGE-LDL-IC (mg/L)6.4 (2.6, 12)5.8 (2.5, 10.8)
MDA-LDL-IC (mg/L)107.3 (42.7, 195.9)98.5 (37.4, 185.9)
oxLDL-IC (mg/L)161.7 (88.6, 295.3)149.4 (80.8, 265.9)
  • Data are median (quartile 1, quartile 3) unless otherwise indicated.

  • *With weights based on the joint distribution of the complications and further adjusted for sex and cohort.